Likarda

Did you know March is National Colorectal Cancer Awareness Month? Colorectal cancer remains one of the most diagnosed cancers worldwide. It’s the leading cause of cancer-related deaths in men and the second in women under 50, highlighting the urgent need for more effective treatment strategies—including targeted drug delivery and advanced cell therapies. At Likarda, we’re exploring how hydrogel encapsulation can push the boundaries of treatment innovation by: ➡️ Enhancing Targeted Drug Delivery – Our customized hydrogel technology improves retention, precision, and immune evasion of therapeutic cells in the tumor microenvironment, potentially increasing treatment effectiveness. ➡️ Optimizing Cell Therapy for CRC – Encapsulation protects and sustains cell-based therapies, ensuring a more prolonged immune response against tumors while reducing off-target effects. We’d love to hear from those working in CRC treatments—What breakthroughs do you see on the horizon for colorectal cancer treatment? What are the biggest challenges in optimizing localized drug release? 👇 Drop your insights in the comments or reach out. We’re always looking to collaborate with experts shaping the future of cancer treatment.

Struggling with poor cell retention or inconsistent dosing in your therapy? You’re not alone. Scaling up cell therapies presents significant challenges, but our advanced encapsulation technology is designed to overcome key hurdles, enhancing stability, delivery, and therapeutic efficacy. By enabling controlled, scalable delivery, we help improve: ✅ Persistence – Keeping therapeutic cells where they’re needed most ✅ Yield – Maximizing efficiency and reducing waste ✅ Function – Enhancing therapeutic impact for better patient outcome

Bringing cell therapies from the lab to real-world application isn’t just about discovery—it’s about overcoming barriers to clinical success. Scaling these therapies requires optimizing delivery without sacrificing quality, efficacy, or consistency. At Likarda, we’re leading the way in hydrogel encapsulation technology, refining solutions for both in vitro and in vivo applications. By enhancing yield, reproducibility, and therapeutic impact, we help ensure that cell-based therapies can be delivered at scale—efficiently and effectively. Let’s explore how we can optimize your therapy. Drop a comment, DM, or email to info@likarda.com to discuss a FREE consultation with our team. #HealthcareInnovation #DrugDevelopment #FutureofMedicine

🧬 BIG NEWS! 🧬 What if a single dose of therapy could last months instead of days? That’s exactly what we’re working on at Likarda—and we’ve just received a major grant to bring this innovation to life! Many infectious diseases require frequent dosing, creating treatment challenges and poor adherence. Our Core-Shell Spherification® platform encapsulates therapeutic cells in a tunable hydrogel system, protecting them from immune clearance while enabling the controlled release of antibodies over an extended period of several months to a year. Why This Changes Everything: 🔹 Immune Protection – Shields cells for extended therapeutic impact. 🔹 Temperature-Stable Hydrogel – Built for durability and controlled release. 🔹 Expanding What’s Possible – Bringing scalable, long-term cell-based therapies closer to reality. 🔗 Read the full press release here: https://lnkd.in/g76dYYEm And this is just the beginning! 🌍 Hit ‘Follow’ to stay updated as Likarda continues to push the boundaries of what’s possible in biotech and global health. #HealthcareInnovation #CellTherapy #InfectiousDisease #DrugDelivery

🚀 Exciting News! 🚀 Likarda and our customer VitalTE are featured in the latest issue of European Pharmaceutical Manufacturer, discussing how hydrogels are transforming hormone delivery! 💡 Our encapsulated hydrogel technology enables slow, controlled hormone release over the course of weeks, providing a more effective and patient-friendly injectable alternative to traditional pellet-based delivery. Preclinical studies indicate that our hydrogel microbeads achieve a similar release rate to pellet delivery, but with one key advantage—no need for an in-office insertion procedure! 🔍 Want to learn more? Check out the article and explore how Likarda is shaping the future of hormone delivery and drug release technologies. #DrugDelivery #Hydrogels #PharmaceuticalInnovation #HormoneTherapy #Biotech #Likarda #VitalTE #European Pharmaceutical Manufacturer

Big solutions start with bold ideas! We’re excited to announce that Likarda has been selected to present at the BioTools Innovator East Coast Pitch Event tomorrow in Boston! Our Founder & President, Dr. Lisa Stehno-Bittel, will take the stage to showcase how Likarda's breakthrough cell therapy delivery technology is transforming the future of healthcare. This event brings together industry leaders, investors, and top innovators in life science tools and diagnostics—all focused on pushing the boundaries of biotech. We’re honored to be part of the conversation and can’t wait to share how our next-gen encapsulation platform is revolutionizing cell therapy. If you’re attending, let’s connect! Looking forward to an exciting day of innovation and collaboration. #BTIRoadTour2025 #CellTherapy #BiotechInnovation #StartupPitch

At Likarda, we don’t just talk about women in leadership—we live it. With a female President, CEO and CCO, we’re proof that when women lead, industries evolve, innovation accelerates, and meaningful change happens. As the world celebrates #InternationalWomensDay on March 8th, we honor the women making strides in science, medicine, and beyond—those who ask the tough questions, challenge the status quo, and push the boundaries of what’s possible. To every woman forging a path in biotech, healthcare, and STEM—keep leading, keep inspiring, and keep changing the world. We see you. We celebrate you. #WomenInSTEM #WomenInScience

What’s next for biopharma in 2025? In the latest installment of "Scrip Asks...", over 140 biopharma leaders—including Likarda CEO Stella K. Vnook—shared their insights on the biggest therapeutic advancements shaping the year ahead. From breakthroughs in oncology and immunology to game-changing innovations in cardiometabolism and neurology, the industry is set for a transformative year. 📖 Read the full article, written by Eleanor Malone, here: https://bit.ly/3F281lk 🔍 What do you think will be the most impactful advancement in biopharma this year? Share your thoughts in the comments! #pharmainnovation #biotech Citeline

The pharmaceutical logistics industry faces a staggering challenge—an estimated $35 billion is lost annually due to temperature-controlled shipping failures. Equipment malfunctions, delays, and packaging issues compromise product integrity, leading to significant financial losses. This is where Likarda's hydrogel solutions can provide, well—a solution! Powered by our patented Core-Shell Spherification® technology, Likarda can create hydrogels that create physical insulators for sensitive pharmaceuticals for cryopreserved products and fresh shipping. One of our most transformative solutions is LiberaSphere™, designed to revolutionize drug transport.  This innovative solution provides: - Cost-Effective Dry Ice Shipping: Eliminating the cost and complications of liquid nitrogen. - Reliable Drug Protection: Protecting cells against temperature shifts and damage. - Precision On-Demand Release: Easy removal with simple rinsing.  LiberaSphere™ is perfect for therapies requiring precise delivery, such as: - Biologic therapies needing global shipment with stable conditions - Temperature-sensitive medications needing robust encapsulation LiberaSphere™ enhances safety and eliminates the risks of compromised shipments. This is not just a logistics solution; it’s a step toward better patient care and operational efficiency. Ready to transform your supply chain? Let’s connect and explore how LiberaSphere™ can safeguard your therapies and reduce losses. #celltherapy #drugdevelopment #biotech

Heading to #DCATWeek2025? Let’s connect! Likarda CEO Stella K. Vnook will be in New York March 17-20, meeting with industry leaders to explore strategic partnerships in drug delivery and formulation. With customizable hydrogel technology, Likarda can help your team enhance stability, optimize therapeutic efficiency, and streamline the logistics of your therapies to drive better outcomes. Let’s set up a time to meet—email svnook@likarda.com. #DCATWeek #PharmaPartnerships  DCAT (Drug, Chemical & Associated Technologies Association)